$-0.18 EPS Expected for Endocyte, Inc. (ECYT) as of May, 9

April 17, 2018 - By Joseph March

During 2017 Q4 the big money sentiment increased to 1.36. That’s change of 1.04, from 2017Q3’s 0.32. 11 investors sold all, 14 reduced holdings as Endocyte, Inc. ratio improved. 15 increased stakes while 19 funds took stakes. Funds hold 19.91 million shares thus 140.76% more from 2017Q3’s 8.27 million shares.
Morgan Stanley has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Prelude Cap Management stated it has 0.01% in Endocyte, Inc. (NASDAQ:ECYT). California Employees Retirement System has 0% invested in Endocyte, Inc. (NASDAQ:ECYT) for 258,100 shs. Partner Fund L P holds 0.35% or 3.44 million shs in its capital. Eam Lc holds 98,034 shs or 0.06% of its capital. Royal Bancorporation Of Canada reported 12,882 shs. Ra Cap Mngmt Ltd Limited Liability Company has invested 1.2% in Endocyte, Inc. (NASDAQ:ECYT). 1.14 million were reported by Blackrock. Alpine Global Management Limited Liability Corporation holds 0.03% of its capital in Endocyte, Inc. (NASDAQ:ECYT) for 33,675 shs. Hilltop Holding Inc stated it has 0.01% in Endocyte, Inc. (NASDAQ:ECYT). 17,079 are owned by State Street. The New York-based Perceptive Advsr Limited Liability Company has invested 0.21% in Endocyte, Inc. (NASDAQ:ECYT). The New York-based Goldman Sachs has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Weiss Asset Mgmt Limited Partnership holds 14,342 shs. Parallax Volatility Advisers Ltd Partnership holds 7,613 shs.

Endocyte, Inc. registered $45,677 net activity with 0 insider purchases and 1 insider sale since March 9, 2018.

Endocyte, Inc. (NASDAQ:ECYT)’s earnings report is anticipated On May, 9., according to RTT. The earnings per share diference is $0.09 or 33.33 % up from last years number. Previous year: $-0.27; Analysts forcast: $-0.18. Analysts at Wall Street see Endocyte, Inc.’s 0.00 % EPS growth compared to $-0.18 earnings per share for last quarter. On during the last trading session the stock decreased $0.29 or 3.05%, reaching $9.23.Currently Endocyte, Inc. is uptrending after 296.90% change in last April 17, 2017. ECYT has also 956,537 shares volume. ECYT outperformed the S&P 500 by 285.35%.

Endocyte, Inc. (NASDAQ:ECYT) Ratings Coverage

Total analysts of 3 have positions in Endocyte (NASDAQ:ECYT) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since February 27, 2018 according to StockzIntelligence Inc Endocyte has 3 analyst reports. On Tuesday, February 27 the firm has “Outperform” rating given by Cowen & Co.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.The firm is valued at $636.59 million. The firm uses its technology to create novel small molecule drug conjugates and companion imaging agents.Last it reported negative earnings. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

Endocyte, Inc. (NASDAQ:ECYT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.